Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACHV vs MGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: ACHV 1 – 5 MGTX Matrix Metrics: ACHV 4 – 6 MGTX

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas MGTX carries 43.7/100 (HOLD) at $8.82 (64.1x Forward P/E, 46.3% operating margin).

  • Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHV vs MGTX
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.82
-3.87% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 69% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 40
RSI-14: 40.5 · SMA20: $9.39 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (ACHV 1 – 5 MGTX)

Columns: Metric · ACHV · MGTX
1. Valuation Multiples ACHV
Forward P/E 35.3x 64.1x
Trailing P/E 35.3x 10.1x
PEG Ratio 17.68x N/M
EV / Revenue N/M 2.0x
2. Growth & Scale MGTX
Revenue Growth (YoY) +0.0% +8608.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $398M
Market Cap $692.8M $844.2M
3. Profitability & Quality MGTX
Gross Margin N/A 97.9%
Operating Margin 0.0% 46.3%
Net Profit Margin 0.0% 19.9%
Return on Equity (ROE) -845.0% 72.2%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$44M -$28M
Cash Flow Margin N/A -7.0%
Net Cash / Leverage $46M Net Cash $51M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGTX
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 88.3% (23rd %ile) 52.9% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity N/A 51.6% of Rev ($205M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHV (4) vs MGTX (6)
Institutional Metric ACHV MGTX Criterion Row Edge
Market Capitalization
Scale
$692.8M $844.2M Larger Scale MGTX
Trailing P/E Ratio
Valuation
35.3x 10.1x Lower Multiple MGTX
Forward P/E Ratio
Valuation
35.3x 64.1x Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+0.0% +8608.6% Higher Growth MGTX
Operating Margin (TTM)
Profitability
0.0% 46.3% Higher Margin MGTX
Net Profit Margin
Profitability
0.0% 19.9% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
-845.0% 72.2% Higher ROE MGTX
52-Week Range Position
Momentum
69% ($3–$9) 25% ($7–$15) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.73β · 62% Vol 1.65β · 69% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
N/A $398M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 97.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.68x PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($46M Net Cash) -$28M ($51M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACHV +2.73 pp
ACHV: -8.5% · MGTX: -11.23%
3M Horizon ACHV +27.43 pp
ACHV: +0.15% · MGTX: -27.28%
6M Horizon ACHV +25.43 pp
ACHV: +21.29% · MGTX: -4.14%
1Y Horizon ACHV +33.14 pp
ACHV: +48.03% · MGTX: +14.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs MGTX. Trailing 12-month operating profitability (ACHV 0.0% vs MGTX 46.3%) and valuation multiples (ACHV 35.3x vs MGTX 64.1x Forward P/E) are benchmarked directly in Pillar 4 below.

ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x
MGTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$398M
Gross Margin97.9%
Op. Margin46.3%
ROE / Fwd P/E72.2% · 64.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published

Investor FAQ ACHV vs MGTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas MGTX carries 43.7/100 (HOLD) at $8.82 (64.1x Forward P/E, 46.3% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY). Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MGTX at +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $398M for MGTX. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus 51.6% of Rev ($205M) (0 disclosures) for MGTX.

ACHV screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus MGTX (72.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.